A randomized double-blind placebo-controlled crossover trial found that a cannabinoid-based oral supplement significantly improved sleep quality, efficiency, and health-related quality of life in adults with subthreshold insomnia symptoms.
Conducted by researchers from the University of North Florida and Jacksonville University, the study included 20 participants who were administered either a cannabinoid supplement (CS) or a placebo for 10 days, followed by a two-week washout period before switching conditions. The supplement contained 3 mg of THC, 6 mg of CBN, 10 mg of CBD, and 90 mg of a proprietary terpene blend.
The results showed that the CS condition led to significant improvements in sleep quality, sleep efficiency, and insomnia symptoms compared to the placebo. Participants also reported enhanced health-related quality of life, including feeling more energetic and experiencing fewer limitations due to poor physical or mental health.
While improvements were noted in measures of mood, anxiety, and stress, these changes were not statistically significant when compared to the placebo.
The study found no adverse effects, suggesting that the cannabinoid formulation was well tolerated. Researchers conclude:
This cannabinoid-based formulation was a well-tolerated oral supplement that may improve adults’ sleep quality/efficiency and health-related quality of life. Larger controlled trials are encouraged to examine the longer-term effects of this supplement in a variety of populations and environments.
For the full study, click here.
